On September 15, 2026 Xspray Pharma reported to have invite investors, shareholders and analysts to an Investor Update in Gothenburg on Friday, October 2, 2026. The event will be hosted by Xspray as a separate investor event at Gothia Towers, at the same time and venue as the ESH-iCMLf John Goldman Conference on Chronic Myeloid Leukemia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will combine a strategy and company progress update by CEO Blake Leitch, new scientific posters explained by CSO and co-founder Per Andersson, and a moderated discussion with two internationally recognized CML experts: Michael J. Mauro, MD, and Jorge Cortes, MD. Both guest speakers are scientific advisors to Xspray and co-authors of Xspray poster abstracts being presented at the Goldman Conference.
The Investor Update will provide a broader view of Xspray’s transition toward commercial oncology execution, including Dasynoc, Nilopki, launch readiness, the current regulatory situation and the market and future role of the HyNap platform. With new scientific data being presented during the Goldman Conference, the event will also give investors the opportunity to hear how leading US clinical CML-experts view the significance of improved targeted therapies in CML.
Date: Friday, October 2, 2026
Venue: Gothia Towers, Gothenburg or participate live online
Presentation: 12:30–14:00 CEST
Light lunch and registration for participants on site from 11:45 CEST
Please register here
When you register, you can choose if you would like to participate on-site or online.
A link will be sent out in advance to registered online participants.
"The Goldman Conference provides a highly relevant scientific setting for a broader Xspray investor update. We look forward to discussing our progress, our commercial priorities and the continued development of Dasynoc, while also providing scientific context from new data being presented during the conference," says Blake Leitch, CEO of Xspray Pharma.
(Press release, Xspray, SEP 15, 2026, View Source [SID1234670872])